Weaponizing natural killer cells for solid cancer immunotherapy
Details
Publication Year 2023-02,Volume 9,Issue #2,Page 111-121
Journal Title
Trends in Cancer
Publication Type
Review
Abstract
Enhancing natural killer (NK) cell-based innate immunity has become a promising strategy for immunotherapy against hard-to-cure solid cancers. Monoclonal antibody (mAb) therapy has been used to activate NK-cell-mediated antibody-dependent cellular cytotoxicity (ADCC) towards solid cancers. Cancer cells, however, can subvert immunosurveillance using multiple immunosuppressive mechanisms, which may hamper NK cell ADCC. Mechanisms to safely enhance ADCC by NK cells, such as utilizing temporary inhibition of receptor endocytosis to increase antibody presentation from target to effector cells can now be used to enhance NK-cell-mediated ADCC against solid tumors. This review summarizes and discusses the recent advances in the field and highlights current and potential future use of immunotherapies to maximize the therapeutic efficacy of innate anticancer immunity.
Publisher
Cell Press
Keywords
Humans; *Killer Cells, Natural; Antibody-Dependent Cell Cytotoxicity; Antibodies, Monoclonal/pharmacology/therapeutic use; *Neoplasms/drug therapy; Immunotherapy; NK cells; antibody therapeutics; antibody-dependent cellular cytotoxicity; solid tumors; tumor microenvironment
Department(s)
Laboratory Research
PubMed ID
36379852
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-06-15 07:24:58
Last Modified: 2023-06-15 07:25:48

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙